Series Highlights
Attendees at Boston 2018
Why Attend
Join the 2nd Annual conference connecting human biotechs with the animal health industry.
Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
Benefits of the Animal Health industry to Biotechs:
Testimonials
"This was an excellent event. As a newbie to animal health this was an eye opener. Some great connections and introductions. I would highly recommend your conference. The right balance of networking and information. Thank you!"
Sean Ekins, CEO, COLLABORATIONS PHARMA
"This conference provided relevant information and has led to a potential collaboration. I thought the conference was well focused. It was time well spent. I learned a lot and had productive networking sessions. The concept of the confluence of Human Biomedical development and Animal health is integral to our business plan. Kalos looks to leverage its proof of concept work as well as safety and tox to create parallel product lines."
George Colberg, CEO, Kalos Therapeutics, Inc.
"A well organized conference that established a strong link between biotechnology innovation and potential veterinary uses.”
Michael G. Palfreyman, Director, R&D Advisory Board, PAFOS PHARMA LLC
WHO SHOULD ATTEND?
HUMAN BIOTECHNOLOGY
Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:
ANIMAL HEALTH
- Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies
- Market Intelligence and Consultancy Providers
INVESTMENT & SERVICE PROVIDERS
- Private Equity & Venture Capital Investors
- Investment Bankers & M&A advisors
- Legal Advisory
Benefits of Attending
FORGE RELATIONSHIPS with animal health executives and human biotechs in prescheduled 1-on-1 meetings, and discuss research collaborations, deallicensing and other business development opportunities
Address unmet and underserved medical needs across human and veterinary health
Human Biotechs
Identify the target disease areas in animal health that your human health assets can serve
Explore opportunities for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships
Learn about the different types of partnerships with animal health, such as research collaborations and out-licensing deals - and how these deals work
Animal Health
Form Partnerships with human health innovators to build your R&D and innovation pipeline.
Identify exciting new technologies in human health that may have translational potential for veterinary medicine - they might be the next blockbuster animal health products!
Hear what past attendees had to say:
Speakers
Scott Brown
Ailis Tweed-Kent
Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as PEPFAR/Office of U.S. Global AIDS Coordinator, London School of Hygiene & Tropical Medicine, and the Global Health Delivery Project. She brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame.
Peter Hanson
Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals. Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses. He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs. Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.
Lewis Gruber
Lewis Gruber is Chief Executive Officer and a founder of SIWA Therapeutics, Inc. (“SIWA”). SIWA is a pre-clinical stage biopharmaceutical company with a first-in-class humanized monoclonal antibody (“mAb”) that binds to a SIWA-identified advanced glycation endproduct target antigen on senescent cells (“SCs”) and removes them. SCs accumulate with aging or exposure to stress and have a causative role in age-related dysfunction and degenerative diseases including. by way of example, many cancers, and neurodegenerative diseases such as Parkinson’s, ALS, and Alzheimer’s Disease, SIWA has the complete sequence of SIWA 318H, which provides the basis for senescent cell clearance in any mammalian species. Prior to founding SIWA, Mr. Gruber was a founder of Arryx, Inc., and served as its CEO from 2000 through 2005 (acquired by a publicly-held company). While Mr. Gruber was at Arryx, it received numerous awards including ones for World Economic Forum Technology Pioneer (2005) and Red Herring Top 100 Innovator for 2004. Prior to Arryx, he was a founder of Hyseq, Inc, a publicly-held genomics company (subsequently merged). He served as Hyseq’s CEO from 1994 through 2000. While CEO, Hyseq completed the largest IPO of a biotechnology company in 1997 (underwritten by Salomon Smith Barney and others) and obtained collaborations for Hyseq totaling over $10 million. The technology was sold to Beijing Genomics Institute.
George Colberg
Jed Hubbs
Sharon Chase
Dr. Sharon Chase is a small animal veterinarian with over a decade of clinical practice experience gained from working in general and emergency hospitals in Massachusetts and Washington, DC. In addition to clinical practice, Dr. Chase served as a reviewer with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for over seven years. She currently works as a regulatory consultant for the veterinary pharmaceutical industry with Schafer Veterinary Consultants, based in Fort Collins, Colorado.
Chris Robillard
Chris has spent the last 3 years in business development at Karyopharm helping to advance clinical stage products to commercialization in both the human and animal oncology settings. Karyopharm has tested multiple products in canine oncology, both to inform clinical design in humans and to seek partners to advance products in canine oncology. Chris has spent the over 10 years in pharma/biotech in various business development and financial roles.
Cheryl London
Dorothy Brown
Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis. At Eli Lilly/Elanco, she now directs companion animal studies across institutions in order to leverage high quality, systematic translational data with the goal of improving both human and animal health.
Erin Wright
Erin Wright is the senior Healthcare Technology & Distribution Equity Research Analyst at Credit Suisse. Her uniquely broad coverage footprint of 30+ companies spans multiple healthcare sub-sectors including companies in Animal Health, Pharmacy Benefit Management, Pharmaceutical and Medical Distribution, Retail Pharmacy, Dental, Information Technology Services, Clinical Laboratories, and Contract Research Organizations. Erin pioneered a commercial franchise in the Animal Health sector, the first on Wall Street to cover the space in a comprehensive fashion, leveraging her broad experience in equity research covering the pharmaceutical supply chain and products. She has been prominently featured in acclaimed peer reviewed journals as a thought-leader in healthcare industries such as Animal Health. Prior to joining Credit Suisse in 2016, Erin was a lead Equity Research Analyst at Bank of America Merrill Lynch for eight years, focusing on specific subsectors within healthcare, including Animal Health, Infection Control, and Dental. Erin received a BA in Economics from Harvard University, with an emphasis on Organismic and Evolutionary Biology. She is an avid golfer and lives in New York City.
Bruce Taillon
Associate Partners
Elanco
Website: http://www.elanco.com
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. We understand the powerful role healthy animals play in making lives better. We support the physical, emotional and social well-being of people thru a balanced diet rich in protein and the companionship of a pet. And, we preserve the health of the planet by helping farmers raise animals more efficiently. Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. Visit us at Elanco.com and EnoughMovement.com.
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees.
For more information, visit www.zoetis.com.
Media Partner
FierceBiotech
Website: http://www.fiercebiotech.com
Read the latest biotechnology articles on biotech industry leaders, emerging biotech companies, FDA decisions, VC deals, and other biotech industry news.
FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval—and all the seed funding, venture capital, licensing deals, IPOs and M&A that happen along the way.
We track tiny, virtual startups and the biggest of Big Pharma, highlighting the accomplishments and acknowledging the defeats that all of them experience on their way to market with a new therapy or device.
The FierceBiotech team transcends the daily as well, with comprehensive coverage of key medical meetings plus special reports that highlight up-and-comers and shed new light on industry heavyweights.
Agenda
You can download our agenda here.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Headline speakers include:
Download Agenda
Venue
Hyatt Regency Boston Harbor, Boston, MA
Venue: Hyatt Regency Boston Harbor
Address: 101 Harborside Drive, Boston, MA 02128
We have arranged a discounted room rate for all event attendees of $239 per night, exclusive of taxes
To make your reservations, please click here
If you need additional assistance, please contact the hotel Reservation Department on +1 877-803-7534 or click here to find contact information by Region.
Please book by 9th March 2019 - after this rates are subject to availability.
If the group rate is no longer available, prevailing rates may be offered for some or all of your dates.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Book a Team to Save More!
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
Payment Terms for Animal Health Investment Europe:
- Please note that a $79 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in USD
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Those offering consultancy or market intelligence services do not qualify for the Start-Up rate.
- PLEASE NOTE – no additional discounts are available on ‘Start-up Company’ pricing. Group discounts are ONLY available on ‘Delegate’ pricing.
- You can view our Cancellation Policy here.
Become a Sponsor
Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
